Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Construction in Progress: 2018-2021

  • Ascendis Pharma A's Construction in Progress fell 20.74% to $2,174 in Q4 2021 from the same period last year, while for Dec 2021 it was $2,174, marking a year-over-year decrease of 20.74%. This contributed to the annual value of $2,174 for FY2021, which is 17.23% down from last year.
  • As of Q4 2021, Ascendis Pharma A's Construction in Progress stood at $2,174, which was down 20.74% from $2,742 recorded in Q4 2020.
  • Ascendis Pharma A's 5-year Construction in Progress high stood at $3.0 million for Q4 2019, and its period low was $2,174 during Q4 2021.
  • In the last 3 years, Ascendis Pharma A's Construction in Progress had a median value of $2,742 in 2020 and averaged $997,837.
  • Per our database at Business Quant, Ascendis Pharma A's Construction in Progress spiked by 1,209.18% in 2019 and then tumbled by 99.91% in 2020.
  • Quarterly analysis of 4 years shows Ascendis Pharma A's Construction in Progress stood at $228,279 in 2018, then spiked by 1,209.18% to $3.0 million in 2019, then slumped by 99.91% to $2,742 in 2020, then fell by 20.74% to $2,174 in 2021.
  • Its last three reported values are $2,174 in Q4 2021, $2,742 for Q4 2020, and $3.0 million during Q4 2019.